Syntheses and antibacterial activity of a series of 3-(pyridine-3-yl)-2- oxazolidinone

European Journal of Medicinal Chemistry

Volumn 40, Issue 2, 2005, Pages 209-214

  Cui, Yingjie ^a,b   Dang, Yaxian ^b   Yang, Yushe ^b   Zhang, Shuhua ^c   Ji, Ruyun ^b  

^a Laboratoire de Pharmacochimie   (France)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c Sichuan Industrial Institute of Antibiotics   (China)

Author keywords

Antibacterial activity; Gram positive organism; Linezolid; Oxazolidinone

Indexed keywords

[N 3 [4 (N ACETYLPIPERAZINYL)PYRIDIN 3 YL] 2 OXO 5 OXAZOLIDINYL]ACETAMIDE; [N 3 [4 (N CARBO TERT BUTOXYPIPERAZINYL)PYRIDIN 3 YL] 2 OXO 5 OXAZOLIDINYL]ACETAMIDE; [N 3 [4 (N CARBOBENZOXYPIPERAZINYL)PYRIDIN 3 YL] 2 OXO 5 OXAZOLIDINYL]ACETAMIDE; [N 3 [4 (N CARBOETHOXYPIPERAZINYL)PYRIDIN 3 YL] 2 OXO 5 OXAZOLIDINYL]ACETAMIDE; [N 3 [4 (N CARBOMETHOXYPIPERAZINYL)PYRIDIN 3 YL] 2 OXO 5 OXAZOLIDINYL]ACETAMIDE; [N 3 [4 (N PIPERAZINYL)PYRIDIN 3 YL] 2 OXO 5 OXAZOLIDINYL]ACETAMIDE; [N 3 [4 [N (4 ACETYLAMINOPHENYLSULFONYL)PIPERAZINYL]PYRIDIN 3 YL] 2 OXO 5 OXAZOLIDINYL]ACETAMIDE; [N 3 [4 [N (4 AMINOPHENYLSULFONYL)PIPERAZINYL]PYRIDIN 3 YL] 2 OXO 5 OXAZOLIDINYL]ACETAMIDE; [N 3 [4 [N (4 NITROPHENYLSULFONYL)PIPERAZINYL]PYRIDIN 3 YL] 2 OXO 5 OXAZOLIDINYL]ACETAMIDE; LINEZOLID; OXAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG SCREENING; DRUG SUBSTITUTION; DRUG SYNTHESIS; ENTEROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; ENTEROCOCCUS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; PYRIDINES; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS;

EID: 13444301218     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejmech.2004.10.012     Document Type: Article

References (16)

1. S. Brickner, D. Hutchinson, M. Barbachyn, P. Manninen, D. Ulanowicz, and S. Garmon J. Med. Chem. 39 1996 673
2. D.J. Diekema, and R.N. Jones Drugs 59 2000 7
3. M.R. Barbachyn, and C.W. Ford Angew Chem. 42 2003 2010 Int. Ed.
4. B. Bozdogan, and P.C. Appelbaum Int. J. Antimicrob. Agents 23 2004 113
5. A.P. Johnson, L. Tysall, M.W. Stockdale, N. Woodford, M.E. Kaufmann, M. Warner, D.M. Livermore, F. Asboth, and F.J. Allerberger Eur. J. Clin. Microbial. Infect. Dis. 21 2002 751
6. C. Auckland, L. Teare, F. Cooke, M.E. Kaufmann, M. Warner, G. Jones, K. Bamford, H. Ayles, and A.P. Johnson J. Antimicrob. Chemother. 50 2002 743
7. S. Tsiodras, H.S. Gold, G. Sakoulas, G.E. Eliopoulos, C. Wennersten, L. Venkataraman, R.C.J. Moellering, and M.J. Ferraro Lancet 358 2001 207
8. P. Wilson, J.A. Andrews, R. Charlesworth, R. Walesby, M. Singer, D.J. Farrell, and M.J. Robbins Antimicrob. Chemother. 51 2003 186
9. B.B. Lohray, V.B. Lohray, B.K. Srivastava, S. Gupta, M. Solanki, P. Kapadnis, V. Takale, and P. Pandya Bioorg. Med. Chem. Lett. 14 2004 3139
10. S.Y. Jang, Y.H. Ha, S.W. Ko, W. Lee, J. Lee, S. Kim, Y.W. Kim, W.K. Lee, and H.J. Ha Bioorg. Med. Chem. Lett. 14 2004 3881
11. B.K. Srivastava, P.B. Kapadnis, P. Pandya, and V.B. Lohray Eur. J. Med. Chem. 39 2004 989
12. (a) R. Bernd, Chem. Abstr. 124 (1997) 289520 (EP 693,491);
13. (b) R. Bernd, Chem. Abstr. 124 (1997) 261021 (EP 694,543);
14. (c) R. Bernd, Chem. Abstr. 127 (1998) 205567 (DE 19604223).
15. G. Sbardella, A. Mai, M. Artico, R. Loddo, M.G. Setzu, and P. La Colla Bioorg. Med. Chem. Lett. 14 2004 1537
16. National Committee for Clinical and Laboratory Standards,Method for dilution antimicrobial susceptibility test for bacteria that grow aerobically, Approved Standard fourth ed, NCCLS USA, 1997, M7-A4.